You are here

Science DOI:10.1126/science.aal5240

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.

Publication TypeJournal Article
Year of Publication2017
AuthorsBullman, S, Pedamallu, CS, Sicinska, E, Clancy, TE, Zhang, X, Cai, D, Neuberg, D, Huang, K, Guevara, F, Nelson, T, Chipashvili, O, Hagan, T, Walker, M, Ramachandran, A, Diosdado, B, Serna, G, Mulet, N, Landolfi, S, Ramon Y Cajal, S, Fasani, R, Aguirre, AJ, Ng, K, Élez, E, Ogino, S, Tabernero, J, Fuchs, CS, Hahn, WC, Nuciforo, P, Meyerson, M
JournalScience
Date Published2017 Nov 23
ISSN1095-9203
Abstract

Colorectal cancers comprise a complex mixture of malignant cells, non-transformed cells and microorganisms. Fusobacterium nucleatum is among the most prevalent bacterial species in colorectal cancer tissues. Here we show that colonization of human colorectal cancers with Fusobacterium and its associated microbiome, including Bacteroides, Selenomonas and Prevotella species, is maintained in distal metastases, demonstrating microbiome stability between paired primary-metastatic tumors. In situ hybridization analysis revealed that Fusobacterium is predominantly associated with cancer cells in the metastatic lesions. Mouse xenografts of human primary colorectal adenocarcinomas were found to retain viable Fusobacterium and its associated microbiome through successive passages. Treatment of mice bearing a colon cancer xenograft with the antibiotic metronidazole reduced Fusobacterium load, cancer cell proliferation and overall tumor growth. These observations argue for further investigation of antimicrobial interventions as a potential treatment for patients with Fusobacterium-associated colorectal cancer.

DOI10.1126/science.aal5240
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/29170280?dopt=Abstract

Alternate JournalScience
PubMed ID29170280